Transgenomic, Amgen Ink Deal to Develop Test for KRAS, NRAS | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic today announced a deal with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer for KRAS and NRAS mutations.

The mutations will be identified with Transgenomic's CE-IVD CRC RAScan kits, which use Surveyor-Wave technology. The test will allow physicians to incorporate tumor mutation status into their treatment decisions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.